PepsiCo: Why The Turnaround Is Finally Taking Hold (Preview)

21% upside potential and a ~4% forward dividend yield support a continued Buy on PepsiCo (PEP). SKU rationalization, selective price cuts and supply-chain optimization are expected to drive volume recovery and long-term margin expansion. GLP-1 weight-loss drug adoption is flagged as a risk to volumes but is seen as mitigated by PEP's single-serve focus and portion-control strategy.

Analysis

SKU rationalization and targeted price elasticity moves shift the P&L leverage: fewer SKUs should raise SKU-level throughput, reduce changeover losses and lower working capital per SKU, which can translate into 50–150bps of incremental EBIT margin within 12–24 months if execution avoids promotional bleed. The real operational optionality is in bottlers and co-packers — higher single-serve mix increases fill-rate predictability and raises utilization of high-speed lines, creating outsized margin capture for larger scale players and squeezing smaller contract packers over the same period.

GLP-1 adoption is a multi-year structural tail risk rather than a binary near-term event; model scenarios where GLP-1 penetration reaches 5–10% of the dieting cohort by year three imply a 2–6% secular hit to snack calories, concentrated in shared/impulse formats. That dynamic favors single-serve and functional/low-calorie innovation, but could leave away-from-home channels and multi-serve SKUs exposed; watch population-level prescription & insurer coverage datapoints as 3–12 month catalysts.

Tactically, margin recovery is fragile to commodity swings and retailer mix-shifts — a 100–150bps bounce in input costs or a retailer push for promotional resets can wipe out a quarter of the expected margin tailwind within 3–6 months. Conversely, sustained shelf rationalization and carry-through promotions by national retailers will compress private-label competitiveness and amplify branded share gains over 9–18 months, creating a clear window for asymmetric positioning.

Key Decisions for Investors

• Long PEP equity (12–18 months): initiate a core position sized to target a 15–20% total return in 12 months while keeping a 10–12% stop. Rationale: capture margin-expansion optionality and preferred-shareholder carry; downside protected by dividend income and operational cadence.
• Pair trade — Long PEP / Short KO (1:1, 12 months): size modestly to exploit superior SKU and routing execution. Risk/reward: if PEP out-executes in SKU rationalization, expect relative total-return outperformance of 8–12%; downside if Coca‑Cola wins pricing/away‑from‑home rebound.
• Options hedge — Buy PEP Jan-2027 LEAP calls (delta ~0.40) financed by selling Jun-2026 calls ~15% OTM: provides leveraged upside participation while funding time decay. Target 2:1 reward-to-funded-cost; exit on 30–40% premium or on missed execution catalysts at 9 months.
• Tactical income — Buy-and-write (6–9 months): accumulate PEP and sell 6–9 month calls ~10–12% OTM to harvest carry if upside is muted near-term. Use proceeds to buy short-dated puts (5–8% OTM) if GLP-1 adoption datapoints accelerate to limit tail exposure.